{Reference Type}: Case Reports
{Title}: Targeted treatment in complex lymphatic anomaly: a case of synergistic efficacy of trametinib and sirolimus.
{Author}: Seront E;Froidure A;Revencu N;Dekeuleneer V;Clapuyt P;Dumitriu D;Vikkula M;Boon LM;
{Journal}: Orphanet J Rare Dis
{Volume}: 19
{Issue}: 1
{Year}: 2024 May 16
{Factor}: 4.303
{DOI}: 10.1186/s13023-024-03211-z
{Abstract}: Repurposing anticancer drugs to vascular malformations has significantly improved patient outcomes. Complex Lymphatic Anomalies (CLA) are part of the spectrum of lymphatic malformations (LMs) that share similar oncogenic mutations to cancer. We report the case of a young patient with highly symptomatic CLA who was initially treated with sirolimus, due to the frequent involvement of the PI3K-AKT-mTOR pathway in CLA pathogenesis. Despite an initial reduction in symptoms, sirolimus progressively lost its effectiveness. After an unsuccessful attempt with trametinib alone, sirolimus was added to trametinib and resulted in a significant, rapid and sustained improvement in symptoms. This suggests that, contrary to current dogmas, combination therapy using sub-therapeutic doses targeting both the PI3K and RAS pathways retains efficacy without generating the toxicity known for combination therapies, and is beneficial in the management of CLAs and potentially other vascular anomalies.